Medicenna Reports Third Quarter Fiscal 2023 Financial Results and Operational Highlights
07 févr. 2023 07h00 HE
|
Medicenna Therapeutics Corp.
Phase 1/2 ABILITY study advancing to sixth dose escalation cohort following positive review of safety and pharmacodynamic data from fifth cohort Initial PK/PD data from ABILITY’s fifth dose escalation...
Medicenna to Present at the 2023 Guggenheim Oncology Conference
31 janv. 2023 07h30 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today...
Medicenna to Announce Third Quarter Fiscal 2023 Financial Results and Operational Highlights on Tuesday, February 7, 2023
26 janv. 2023 07h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...
Medicenna Strengthens Intellectual Property Protection for MDNA11 and BiSKITs™ Programs with Issuance of U.S. Patent
05 janv. 2023 09h14 HE
|
Medicenna Therapeutics Corp.
- Patent covers methods of treating cancer with an IL-2 Superkine and PD1/PDL1 or CTLA-4 checkpoint inhibitor, administered in combination or as a single agent BiSKIT™ TORONTO and HOUSTON, Jan. 05,...
Medicenna Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 ABILITY Study of MDNA11 at the SITC Annual Meeting
10 nov. 2022 09h00 HE
|
Medicenna Therapeutics Corp.
- MDNA11’s selectivity and dose-dependent stimulation of anti-cancer immune cells indicates potential for increased anti-tumor activity with continued dose escalation - New data reaffirm MDNA11’s...
Medicenna Reports Second Quarter Fiscal 2023 Financial Results and Operational Highlights
04 nov. 2022 07h00 HE
|
Medicenna Therapeutics Corp.
- Results from low and mid-dose escalation cohorts in Phase 1/2 ABILITY study show tumor control in 5 of 14 evaluable patients, including a confirmed partial response in pancreatic cancer - $40...
Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
28 oct. 2022 07h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...
Medicenna to Announce Second Quarter Fiscal 2023 Financial Results and Operational Highlights on Friday, November 4, 2022
25 oct. 2022 07h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...
Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting
05 oct. 2022 08h05 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today...
Medicenna Extends Period to Exercise Certain Warrants
30 sept. 2022 07h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced...